Klaus Wormuth, Fanny Gaston, Melanie Gauthier, Veronique Cantin, Nelly Montenay
{"title":"Best Practices to Quantify and Identify Particulate Matter on the Interior Surfaces of Single-Use Systems.","authors":"Klaus Wormuth, Fanny Gaston, Melanie Gauthier, Veronique Cantin, Nelly Montenay","doi":"10.5731/pdajpst.2022.012755","DOIUrl":null,"url":null,"abstract":"<p><p>The manufacturing of a wide range of biopharmaceuticals, from antibodies and vaccines to cell-based therapies, increasingly takes place in single-use processing equipment. Manufactured in clean rooms and sealed and sterilized, single-use systems (SUSs) are ready-to-use and easily scalable. Controls in the \"clean-build\" manufacturing of SUSs reduce the probability of occurrence of particulate matter in SUSs. However, the size, complexity, and limited transparency of SUSs clearly limit the detectability of particulate matter on the interior (fluid-contacting) surfaces of a SUS during a visual inspection, as demonstrated in a recent study. In applications downstream of final filters or in aseptic processing, particulate matter on the surfaces of a SUS could detach and contaminate the final drug product. A realistic assessment of this risk requires reliable test methods that quantify and identify particulate matter present on the interior surfaces of SUSs. Clearly problematic is the common certification of the cleanliness of a SUS via a force-fit adaptation of the pharmacopeial standard USP <788> entitled \"Particulate Matter in Injections\". USP <788> does not describe a procedure for extraction of particulate matter from the interior surfaces of SUSs. In addition, application of Method 1 Light Obscuration significantly limits the probability of detection for particles in the visible size range (≥ 100 µm). In this article, we describe best practices for extracting, counting, sizing, and chemically identifying particulate matter on the interior surfaces of SUSs. Highly effective procedures for the extraction of particulate matter result from application of the qualification methodology described in a recently published ASTM standard. Filtration of the liquid extract concentrates particulate matter onto the surface of a membrane filter, allowing rapid particle counting and sizing using automated membrane microscopy, along with detailed chemical identification using infrared microscopy and/or automated confocal Raman microscopy.</p>","PeriodicalId":19986,"journal":{"name":"PDA Journal of Pharmaceutical Science and Technology","volume":" ","pages":"90-99"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PDA Journal of Pharmaceutical Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5731/pdajpst.2022.012755","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The manufacturing of a wide range of biopharmaceuticals, from antibodies and vaccines to cell-based therapies, increasingly takes place in single-use processing equipment. Manufactured in clean rooms and sealed and sterilized, single-use systems (SUSs) are ready-to-use and easily scalable. Controls in the "clean-build" manufacturing of SUSs reduce the probability of occurrence of particulate matter in SUSs. However, the size, complexity, and limited transparency of SUSs clearly limit the detectability of particulate matter on the interior (fluid-contacting) surfaces of a SUS during a visual inspection, as demonstrated in a recent study. In applications downstream of final filters or in aseptic processing, particulate matter on the surfaces of a SUS could detach and contaminate the final drug product. A realistic assessment of this risk requires reliable test methods that quantify and identify particulate matter present on the interior surfaces of SUSs. Clearly problematic is the common certification of the cleanliness of a SUS via a force-fit adaptation of the pharmacopeial standard USP <788> entitled "Particulate Matter in Injections". USP <788> does not describe a procedure for extraction of particulate matter from the interior surfaces of SUSs. In addition, application of Method 1 Light Obscuration significantly limits the probability of detection for particles in the visible size range (≥ 100 µm). In this article, we describe best practices for extracting, counting, sizing, and chemically identifying particulate matter on the interior surfaces of SUSs. Highly effective procedures for the extraction of particulate matter result from application of the qualification methodology described in a recently published ASTM standard. Filtration of the liquid extract concentrates particulate matter onto the surface of a membrane filter, allowing rapid particle counting and sizing using automated membrane microscopy, along with detailed chemical identification using infrared microscopy and/or automated confocal Raman microscopy.
从抗体、疫苗到细胞疗法等各种生物制药的生产,越来越多地采用一次性使用加工设备。一次性使用系统(SUS)在洁净室中制造,经过密封和灭菌处理,即开即用,易于扩展。在 SUS 的 "洁净制造 "过程中进行控制,可降低 SUS 中出现微粒物质的概率。然而,SUS 的尺寸、复杂性和有限的透明度明显限制了目测 SUS 内部(与流体接触)表面微粒物质的可探测性,最近的一项研究就证明了这一点。在最终过滤器的下游应用或无菌加工中,SUS 表面的微粒物质可能会脱落并污染最终药物产品。要对这种风险进行实际评估,就必须采用可靠的检测方法,对 SUS 内表面的微粒物质进行量化和鉴定。通过强行修改药典标准 USP 中题为 "注射剂中的微粒物质 "的规定来认证 SUS 的清洁度显然是有问题的。USP 没有描述从 SUS 内表面提取微粒物质的程序。此外,方法 1 光掩蔽的应用大大限制了对可见尺寸范围(≥ 100 µm)内微粒的检测概率。在本文中,我们将介绍对 SUS 内表面的微粒物质进行提取、计数、测定和化学鉴定的最佳方法。采用最近出版的 ASTM 标准中描述的鉴定方法,可以高效提取颗粒物质。对液体提取物进行过滤,将颗粒物质浓缩到膜过滤器的表面上,这样就可以使用自动膜显微镜对颗粒进行快速计数和测定,并使用红外显微镜和/或自动共焦拉曼显微镜进行详细的化学鉴定。